Biothera Pharmaceuticals, Inc.
http://www.biothera.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biothera Pharmaceuticals, Inc.
Glenmark Follows BeiGene, Nimbus With Early Stage HPK1 Inhibitor
Glenmark is set to initiate a Phase I study for its inhibitor of immuno-oncology target hematopoietic progenitor kinase 1 (HPK1), a segment that has seen increased activity over the recent past with BeiGene, Nimbus and Treadwell Therapeutics among those advancing their molecules.
Tech Transfer Roundup: MD Anderson, Moffitt Lead Busy Academic Cancer Partnering Space
MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.
Coronavirus Update: Canadian Evusheld Supply Deal, Nuvaxovid EU Shipments
The US places certain limits on the use of GSK's Xevudy, while Canada signs a supply deal for another antibody therapy, AstraZeneca's Evusheld. Meanwhile, Novavax starts EU shipments of its vaccine and the UK funds ConserV's pan-coronavirus vaccine.
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Biopolymer Engineering, Inc.